{"id":"https://openalex.org/W2003163303","doi":"https://doi.org/10.1002/bdd.2510150609","title":"The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers","display_name":"The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers","publication_year":1994,"publication_date":"1994-08-01","ids":{"openalex":"https://openalex.org/W2003163303","doi":"https://doi.org/10.1002/bdd.2510150609","mag":"2003163303","pmid":"https://pubmed.ncbi.nlm.nih.gov/7993989"},"language":"en","primary_location":{"id":"doi:10.1002/bdd.2510150609","doi":"https://doi.org/10.1002/bdd.2510150609","is_oa":false,"landing_page_url":"https://doi.org/10.1002/bdd.2510150609","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & Drug Disposition","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108391656","display_name":"Peter H. Degen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"P. H. Degen","raw_affiliation_strings":["Ciba-Geigy Limited, Pharmaceuticals Division, Basel, Switzerland","Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018533252","display_name":"G\u00e9rard Flesch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Flesch","raw_affiliation_strings":["Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"J.\u2010M. Cardot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J.\u2010M. Cardot","raw_affiliation_strings":["Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081056394","display_name":"C. Czendlik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Czendlik","raw_affiliation_strings":["Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082023099","display_name":"W. Dieterle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Dieterle","raw_affiliation_strings":["Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba\u2014Geigy Limited, Preclinical Development, Pharmaceuticals Division, Basel, Switzerland","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5108391656"],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.904,"has_fulltext":false,"cited_by_count":32,"citation_normalized_percentile":{"value":0.72475928,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"15","issue":"6","first_page":"519","last_page":"526"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9077000021934509,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9077000021934509,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.05270000174641609,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.024900000542402267,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oxcarbazepine","display_name":"oxcarbazepine","score":1.0},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.7490000128746033},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9620000123977661},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.9240000247955322},{"id":"https://openalex.org/keywords/breakfast","display_name":"breakfast","score":0.4880000054836273},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5680000185966492},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8100000023841858}],"concepts":[{"id":"https://openalex.org/C2781176495","wikidata":"https://www.wikidata.org/wiki/Q176301","display_name":"Oxcarbazepine","level":4,"score":0.98054039478302},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7265986204147339},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7240602374076843},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5653704404830933},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.5121593475341797},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5086373090744019},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.503616988658905},{"id":"https://openalex.org/C2994127763","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Antiepileptic drug","level":3,"score":0.4741736650466919},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4650844931602478},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46005934476852417},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.4506618082523346},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37600380182266235},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.3531188368797302},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3082358241081238},{"id":"https://openalex.org/C2779253243","wikidata":"https://www.wikidata.org/wiki/Q410412","display_name":"Carbamazepine","level":3,"score":0.24436232447624207},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.11558151245117188},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000078330","descriptor_name":"Oxcarbazepine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002220","descriptor_name":"Carbamazepine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004435","descriptor_name":"Eating","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/bdd.2510150609","doi":"https://doi.org/10.1002/bdd.2510150609","is_oa":false,"landing_page_url":"https://doi.org/10.1002/bdd.2510150609","pdf_url":null,"source":{"id":"https://openalex.org/S57691945","display_name":"Biopharmaceutics & Drug Disposition","issn_l":"0142-2782","issn":["0142-2782","1099-081X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & Drug Disposition","raw_type":"journal-article"},{"id":"pmid:7993989","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7993989","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biopharmaceutics & drug disposition","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W3624395","https://openalex.org/W219357105","https://openalex.org/W1967322264","https://openalex.org/W1991459693","https://openalex.org/W1994247742","https://openalex.org/W2004891879","https://openalex.org/W2006998103","https://openalex.org/W2093386822","https://openalex.org/W2108083324"],"related_works":["https://openalex.org/W2097337757","https://openalex.org/W1985510281","https://openalex.org/W1989869913","https://openalex.org/W2086608015","https://openalex.org/W2093386822","https://openalex.org/W2074838078","https://openalex.org/W3097852640","https://openalex.org/W1971452852","https://openalex.org/W2050698601","https://openalex.org/W2363610374"],"abstract_inverted_index":{"The":[0,146,168,184],"effect":[1,69,186],"of":[2,7,27,30,52,166,187,192,196],"food":[3,180,188],"on":[4,189],"the":[5,8,47,53,58,67,81,113,129,157,171,190],"pharmacokinetics":[6],"antiepileptic":[9],"oxcarbazepine":[10,31,141,174,193],"(OXC)":[11],"was":[12,132,142,151,170,175],"investigated":[13],"in":[14,56,70,181],"healthy":[15,18,182],"volunteers.":[16,183],"Six":[17],"male":[19],"volunteers":[20,83,115],"were":[21,72,105,160],"treated":[22],"with":[23,144],"single":[24],"peroral":[25],"doses":[26],"600":[28],"mg":[29],"(Trileptal)":[32],"after":[33,95,126,179],"overnight":[34],"fasting":[35],"or":[36,178],"a":[37,96],"fat-":[38],"and":[39,84,116,136],"protein-rich":[40],"breakfast.":[41,98,127],"Mean":[42,99],"(+/-":[43,100],"SD)":[44,101],"areas":[45],"under":[46],"plasma":[48],"concentration-time":[49],"curves":[50],"(AUC)":[51],"major":[54],"component":[55],"plasma,":[57],"active":[59],"monohydroxy":[60],"metabolite":[61],"(MHD),":[62],"which":[63,149],"is":[64],"responsible":[65],"for":[66],"therapeutic":[68,198],"man,":[71],"672":[73],"(25)":[74],"mumol":[75,87,108,119],"L-1":[76,88,109,120],"h":[77,89],"when":[78,93,110,124,140],"given":[79,94,111,125,143,176],"to":[80,112],"fasted":[82,114],"780":[85],"(31)":[86],"(p":[90,121],"=":[91,122],"0.042)":[92],"substantial":[97],"maximum":[102],"concentrations":[103],"(Cmax)":[104],"25.5":[106],"(4.8)":[107],"31.4":[117],"(5.3)":[118],"0.025)":[123],"Thus,":[128],"average":[130],"AUC":[131],"increased":[133],"by":[134,138,163],"16%":[135],"Cmax":[137,150],"23%":[139],"food.":[145,167],"times":[147],"at":[148],"reached":[152],"(tmax)":[153],"as":[154,156],"well":[155],"terminal":[158],"half-lives":[159],"not":[161],"influenced":[162],"concomitant":[164],"intake":[165],"tolerability":[169],"same":[172],"whether":[173],"before":[177],"slight":[185],"kinetics":[191],"should":[194],"be":[195],"little":[197],"consequence.":[199]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}